Previous reports have shown that IMP is significantly increased in patients with type 2 diabetes and impairs glucose tolerance and insulin signaling when administered to mice, suggesting that it acts as a negative regulator (12). The gene discussed is INS; the disease is type 2 diabetes mellitus.